Clinical outcomes of pomalidomide ‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China

ConclusionsIn real-world settings, Pom-based, Dara-based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara-based therapy yielded superior clinical response and PFS compared to Pom-based therapy.

https://onlinelibrary.wiley.com/doi/10.1002/cam4.7232?af=R

Source: Cancer Medicine - May 3, 2024 Category: Cancer & Oncology Authors: Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Yi Zhao, Yi Li, Wenjun Wu, Zhen Cai Tags: RESEARCH ARTICLE Source Type: research